PARIS – Wishbone SA closed a $3 million funding round, which should allow it to obtain the CE mark prior to launching its range of products in Europe based on bone regeneration technology for reconstructive dental surgery. “Thanks to this round, we are ramping scale and moving from R&D to the commercialization phase in Europe,” Daniel Bee, CEO of Wishbone, told BioWorld.
Financings ramped up dramatically in 2015 with $68 billion collected, but the amount does not touch biopharma investment in the last two years. The industry has raised $113 billion in 2021, down from the $134.5 billion full year 2020 total, but more than every five-year combination total from the years 2000 to 2014. It is an increase of 65% over 2015, 200% over 2016, 118% over 2017, 68% over 2018 and 95% over 2019. Both IPOs ($23.7 billion) and venture capital rounds ($37.8 billion) have hit all-time records this year. But will the onslaught of money continue for the industry?
PERTH, Australia – Health care artificial intelligence (AI) company Harrison.ai has raised AU$129 million (US$97 million) in a series B round that will expand the company’s global footprint by commercializing its comprehensive clinical AI applications.
Medimaps Group SA has landed $20 million to expand its portfolio of bone health imaging software. The round was led by Swisscanto Invest, the asset management arm of the Zürcher Kantonalbank group, with participation from the Swiss Entrepreneurs Fund, Swisscom Ventures, and Verve Ventures. The company’s flagship product TBS (trabecular bone score) Insight is an artificial intelligence-powered medical software which provides information on bone quality from routine DXA and X-ray images.
LONDON – Aviadobio Ltd. has raised $80 million in a series A round to take a precision microdosed gene therapy for treating familial frontotemporal dementia into a phase I/II clinical trial.
Tune Therapeutics Inc. launched with $40 million in initial financing and plans to pursue both rare and complex disease indications with a series of epigenetic editors that employ CRISPR-Cas9 DNA recognition to modulate gene expression in a targeted fashion, without introducing potentially problematic DNA strand breaks or changes to the genetic code.
RSS
